Kseroderma Pigmentozum, Epidermodisplasia Verrusiformis ve D Vitamini
Özet
Kseroderma pigmentozum (KP) ve Epidermodisplasia verrusiformis (EV), DNA onarım mekanizmalarındaki genetik bozukluklar ve human papilloma virüsüne (HPV) karşı hassasiyetle karakterize, otozomal resesif geçiş gösteren nadir deri hastalıklarıdır. KP hastalarında erken yaşta ultraviyole (UV) ışınlarının tetiklediği cilt, mukoza kanserleri ve progresif nörodejenerasyon görülürken; EV'li hastalarda özellikle skuamöz hücreli deri kanseri (SHK) riski belirgin şekilde artış göstermektedir. Her iki hastalık grubunda da premalign ve malign lezyonların tedavisinde cerrahi müdahaleler, kriyoterapi ve topikal ajanlar gibi yöntemler klinik yönetimde temel rol oynamaktadır. KP hastalarında güneş ışınlarından sıkı ve sürekli korunma gerekliliği, deride de novo D vitamini sentezini engelleyerek ciddi vitamin D eksikliklerine yol açmaktadır. Yapılan klinik çalışmalar, KP popülasyonunda D vitamini düzeylerinin kritik seviyelerde olduğunu ve bu hastalara oral D vitamini takviyesi yapılmasının gerekliliğini ortaya koymaktadır. Son yıllarda yapılan araştırmalar, kalsemik yan etkileri sınırlandırılmış yeni D vitamini analoglarının tek başına veya sistemik retinoidler ile kombine edilerek topikal kullanımının, antineoplastik ve immünmodülatuar etkileri sayesinde premalign ve malign deri tümörlerinin gelişimini önlemede ve tedavisinde umut verici sonuçlar sağladığını göstermektedir.
Xeroderma pigmentosum (XP) and Epidermodysplasia verruciformis (EV) are rare, autosomal recessive skin disorders characterized by genetic mutations in DNA repair mechanisms and hypersensitivity to human papillomavirus (HPV) infections, respectively. XP patients exhibit early-onset skin and mucosal malignancies triggered by ultraviolet (UV) radiation alongside progressive neurodegeneration, whereas EV patients demonstrate a significantly increased risk of squamous cell carcinoma (SCC). For both patient groups, surgical interventions, cryotherapy, and various topical agents play foundational roles in managing premalignant and malignant lesions. The stringent and lifelong sun protection required by XP patients prevents de novo vitamin D synthesis in the skin, leading to severe and prevalent vitamin D deficiencies. Clinical studies highlight critically low vitamin D levels in XP populations, making oral vitamin D supplementation highly recommended. Recent research indicates that utilizing novel vitamin D analogs with minimized calcemic side effects—either as monotherapy or combined with systemic retinoids—shows promising antineoplastic and immunomodulatory results in preventing and treating cutaneous malignancies.
Referanslar
DiGovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol 2012;132:785-96.
Lehmann AR, McGibbon D, Stefanini M. Xerodema pigmentosum. Orphanet J Rare Dis. 2011 Nov 1; 6: 70-1.
Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. DNA Repair (Amst) 2004; 3: 183-87.
Cleaver JE: Xeroderma pigmentosus: variants with normal DNA repair and normal sensitivity ultraviolet light. J Invest Dermatol 1972; 58: 124-8.
Kleijer WJ, Laugel V, Berneburg M et al. Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA repair (Amst) 2008; 7(5):744-50.
Khatri ML, Bemghazil M, Shafi M, Machina A. Xeroderma pigmentosum in Libya. Int J Dermatol 1999; 38: 520-4.
Ü Gül, A Kılıç, M Gönül et al. Xeroderma pigmentosum: a Turkish case series. Int J Dermatol 2007; 46:1125-8.
Bradford PT, Goldstein AM, Tamura D, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet 2011; 48: 168-76.
Olson MT, Puttgen KB, Westra WH. Angiosarcoma arising from the tongue of an 11-year-old girl with xeroderma pigmentosum. Head Neck Pathol 2012; 6: 255-7.
Kraemer KH, DiGiovanna JJ. Forty years of research on xeroderma pigmentosum at the US National Institutes of Health. Photochem Photobiol 2015; 91: 452-9.
Goyal JL, Rao VA, Srinivasan R, Agrawal K. Oculocutaneous manifestations in xeroderma pigmentosa. Br J Ophthalmol 1994; 78: 295-7.
Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symptoms and natural course of xeroderma pigmentosum. Brain 2008; 131:1979-89.
Lowell, A. Fitzpatrick’s Dermatology In General Medicine (eight edit). 2012. The McGraw- Hill Companies, China. Chapter 139:2568-71.
Merideth M, Tamura D, Angra D et al. Reproductive Health in Xeroderma Pigmentosum: Features of Premature Aging. Obstet Gynecol. 2019;134(4):814-19.
Kuwabara A, Tsugawa N, Tanaka K et al. High prevalence of vitamin D deficiency in patients with xeroderma pigmetosum-A under strict sun protection. Eur J Clin Nutr. 2015; 69(6):693-6.
Hoesl M, Dietz K, Röcken M, Berneburg M. Vitamin D levels of XP-patients under stringent sun-protection. Eur J Dermatol. 2010; 20 (4):457-60.
Mohamed A, Bhargava A, Chaurasia S.Vitamin D supplementation in patients with xeroderma pigmentosum. Indian J Ophthalmol. 2019; 67(2):308-9.
Reichrath J. Sunlight, skin cancer and vitamin D: What are the conclusions of recent findings that protection against solar ultraviolet (UV) radiation causes 25-hydroxyvitamin D deficiency in solid organ-transplant recipients, xeroderma pigmentosum, and other risk groups? J Steroid Biochem Mol Biol. 2007 ;103 (3-5):664-7.
Majewski S, et al. Vitamin D analogs in cutaneous malignancies. Curr Pharm Des. 2000; 6:829-38.
Burgdrof. W.H.C. Braun-Falco’s Dermatology (third edit). 2009. Spinger Medizin Verlag, Italy. Chapter 8: 71-2.
Imahorn E, Yüksel Z, Spoerri I et al. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol. 2017; 31:1722-26.
Ramoz N, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002; 32: 579-81.
Youssefian L, Vahidnezhad H, Mahmoudi H et al. Epidermodysplasia Verruciformis: Genetic Heterogeneity and EVER1 and EVER2 Mutations Revealed by Genome-Wide Analysis. J Invest Dermatol. 2019;139(1):241-4
de Jong SJ, Créquer A, Matos I et al. The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to β-papillomaviruses. J Exp Med. 2018 3;215(9):2289-310.
Lazarczyk M, Pons C, Mendoza JA et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med. 2008;205(1):35.
Mitsuishi T, Ohara K, Suzuki T et al. Epidermodysplasia verruciformis with keratoacanthoma, Bowen's disease and squamous cell carcinoma: isolation of high-risk types of HPV 5 and unknown type of human papillomavirus. J Eur Acad Dermatol Venereol. 2008;22(9):1126-7.
de Oliveira WR, Festa Neto C, Rady PL et al. Clinical aspects of epidermodysplasia verruciformis.
J Eur Acad Dermatol Venereol. 2003;17(4):394-8.
Ü Gül, A Kılıç, M Gönül et al. Clinical aspects of epidermodysplasia verruciformis and review of the literatüre. Int J Dermatol 2007; 46 (10): 1069-72.
Tejas Patel, L. Katie Morrisona, Peter Radya et al.Tyring Epidermodysplasia verruciformis and susceptibility to HPV. Disease Markers 29.2010;199-206
Rallis E, Papatheodorou G, Bimpakis E et al. Systemic low-dose isotretinoin maintains remission status in epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol. 2008;22(4):523-5.
Serarslan G, Balci DD, Homan S. Acitretin treatment in acrokeratosis verruciformis of Hopf.
J Dermatolog Treat. 2007;18(2):123-5.
Swati S, Sowjanya K, Sunaina SA et al. Epidermaodysplasia Verruciformis-A Genetic Disorder. Sys Rev Pharm. 2017;8(1):71-5.
Heratizadeh A, Völker B, Kupsch E et al. [Successful symptomatic treatment of epidermodysplasia verruciformis with imiquimod 5% cream]. Hautarzt. 2010;61(12):1052-5.
Karrer S, Szeimies RM, Abels C et al. Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol. 1999;140(5):935-8.
Rajabi MT, Ghasemi H, Safizadeh M et al. Conjunctival squamous cell carcinoma with intraocular invasion after radiotherapy in epidermodysplasia verruciformis. Can J Ophthalmol. 2014;49(2):43-6.
Hayashi J, Matsui C, Mithuishi C et al. Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol. 2002;41(11):817-20.
Kamradt J, Rafi L, Mitschele T et al. Analysis of the vitamin D system in cutaneous malignancies. Recent Results Cancer Res. 2003;164:259-69.
J C Sterling, S Gibs, S S Haque Hussain et al. British Association of Dermatologists’ guidelines for the management of cutaneous warts 2014. B J Dermatol.2014;171:696-712.
